"Pharmaceutical Speed Reading Society" Sanofi new crown vaccine received $2.1 billion to fund the domestic PD-1 performance is amazing.

August 2, 2020 / Medical Information List: Anti-tumor drug "restricted use" requirements will be further clarified, Novartis on gene regulation therapy for the treatment of neurological diseases such as autism and Sangamo, AstraZenewan / Sanofi respiratory cytovirus monoantigenic clinical results positive ... Daily fresh medicine news, quick reading with you to pay attention to! Part 1 Policy Briefing Anti-Tumor Drug "Restricted Use" requirements will be further clarified a few days before the National Health Council issued the "Clinical Application of Anti-Tumor Drugs Management Measures" (draft for comments), or a large number of drugs will be included in the list of key regulatory and restricted use.
(National Health Care Commission) National Health Care Commission to adjust the configuration of large-scale medical equipment planning 31, the National Health Care Commission issued the latest news, decided to 2018-2020 large-scale medical equipment configuration planning adjustment.
adjustment, 2018-2020 Class A-B large-scale medical equipment planning 12768 units, of which: Class A large-scale medical equipment configuration planning 281 units, Class B large-scale medical equipment configuration planning 12487 units.
(National Health And Health Commission) low-value consumables into the band volume procurement day, Taiyuan City Medical Insurance Management Service Center issued "Taiyuan - Jinzhong - Zhangzhou medical institutions medical supplies centralized belt volume procurement project transaction results publicity", from the relevant transaction results, low-value consumables also included in the centralized belt volume procurement.
(Taiyuan City Medical Insurance Management Service Center) Sichuan many large hospitals were found to split the number of hospitalizations recently, Sichuan disclosed some public hospitals and health insurance fund audit, the conclusion is: the effect of fee control policy is not obvious, health insurance fund management is weak.
20 hospitals split patients into multiple hospitalizations in order to circumvent the control standards of inpatient medical expenses and length of stay.
(See The Medical Profession) Part 2 production of the observed Sanofi/GSK new coronary pneumonia vaccine received $2.1 billion from the U.S. government on the 31st, Sanofi/GSK in cooperation with the U.S. government to accelerate the development and production of COVID-19 vaccine based on recombinant protein technology.
U.S. government will contribute $2.1 billion, more than 50 percent of which will be used to support vaccine development, with the remainder going to the large-scale production and transportation of 100 million doses of the vaccine.
(Pharmaceutical Rubik's Cube) Xindili second quarter 500 million first-half sales close to the full year of O drugs, Xinda Bio announced second-quarter results, the first quarter of 400 million, the second quarter of 500 million, Xinda PD-1 Xindili sales in the first half of this year has been close to last year's full-year 1 billion yuan, but also close to O pharmaceutical sales in China in 2019, the growth rate of domestic PD-1 is surprising.
's partnership with Sangamo therapeutics to treat neurological disorders such as autism, Sangamo Therapeutics announced a globally licensed partnership with Novarro to develop and commercialize gene regulatory therapy to treat autism spectrum disorders and a variety of other neurodevelopmental disorders.
this collaboration will use Sangamo's proprietary zinc finger protein transcription factor technology to achieve the desired therapeutic effect by raising or activating certain key genes in neurodevelopmental disorders that are under-expressed.
(Pharmaceuticals) Qilu Pharmaceuticals was granted an exclusive license by Vivineum Greater China on The 31st, and Qilu Pharmaceuticals entered into an exclusive licensing agreement with Sesen Bio to develop the drug for non-intra-intrusive bladder cancer and other types of cancer that do not respond to the card-mediated seedlings in the exclusive interest of the latter in the greater China region.
the deal amounted to $35 million.
(Pharmaceutical Mission) Part 3 Drug News AstraZenein/Sanofi Respiratory Synoptic Virus Monoithrogenic IIB Phase Clinical Results Positive Recently, the New England Journal of Medicine published online positive data from a Phase Iib clinical trial developed by Sanofi in collaboration with AstraZeneff.
results showed that in the RSV epidemic season, single-dose intramuscular injections significantly reduced the rate of RSV-induced lower respiratory tract infections and hospitalizations in healthy prenatal children compared to placebos.
(Bio Valley) Tiandi Bio-Long-Acting Growth Hormone in China submitted a phase 3 registration trial application CDE for the latest publicity, Tiandi Biological Class 1 biological new drug TJ101 injection submitted a clinical trial application.
This is a long-acting growth hormone for the treatment of growth hormone deficiency in children, and this declared clinical trial is a Phase 3 registered study to assess the efficacy, safety and pharmacodynamics of TJ101 for PGHD.
(Pharmaceutical Mission Hills)